Stock listing

Dusseldorf:60Q Captor Therapeutics SA Aktie

German listing (Dusseldorf) of Captor Therapeutics SA · home listing GPW:CTX

Follow Captor Therapeutics SA into a list and get an email when it puts out news.

Home listing price · GPW:CTX

52.00 PLN -0.30 (-0.6%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, GPW:CTX

Past year +1.2% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
50.50 – 53.10 PLNNov 20, 2026
Volume
6,654 sharesNov 20, 2026
Market cap
329.3M PLNAt the close on Nov 20, 2026 · price × 6.33M shares outstanding
52-week range
48.10 – 89.20 PLNLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
317,397 PLNMedian day 2,556 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Captor Therapeutics SA logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
GPW:CTX · Home52.00 PLN-0.30 (-0.6%)6,65453.1053.1050.5052.30Close on Nov 20, 2026
Frankfurt:60Q€11.62 EUR-0.22 (-1.9%)—€11.44€11.62€11.44€11.84Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · GPW:CTX · PLN, adjusted for splits

DayCloseChange%OpenHighLowVolume
52.00-0.30-0.6%53.1053.1050.506,654
52.30+0.30+0.6%51.3053.1051.301,433
52.000.000.0%53.5053.5051.301,514
52.00-2.30-4.2%52.5053.8052.002,747
54.30-0.70-1.3%54.9054.9052.309,000
55.00+2.60+5.0%52.4055.0051.504,032
52.40-1.20-2.2%53.0054.9051.402,824
53.60-0.40-0.7%55.9055.9052.70715
54.00-1.00-1.8%52.6055.0052.102,599
55.00+4.20+8.3%51.0056.0051.0011,835
50.80+0.70+1.4%50.0051.0050.004,479
50.10-0.90-1.8%51.5051.5049.005,547
51.00-2.00-3.8%53.0053.0050.205,354
53.00-0.70-1.3%53.7054.3052.202,145
53.70-1.20-2.2%54.4055.0053.708,196
54.90-1.10-2.0%55.9055.9054.302,311
56.00-0.20-0.4%56.0057.0055.709,632
56.20-0.80-1.4%55.5057.5055.502,556
57.00-0.90-1.6%57.1057.1056.101,701
57.90-0.70-1.2%58.7058.9056.702,142
58.600.000.0%58.9058.9056.80998
58.60+2.20+3.9%55.8059.6055.203,792
56.40-0.60-1.1%56.6059.5053.308,567
57.00-1.40-2.4%58.4058.9057.0020,526
58.40-1.20-2.0%59.6059.8056.6026,322
59.60-0.40-0.7%59.6060.9059.609,991
60.00-1.30-2.1%60.0062.0059.6030,504
61.30-2.70-4.2%64.1064.4059.2021,957
64.00-1.50-2.3%65.4066.7062.5010,032
65.50-1.50-2.2%66.4067.0065.507,277
67.00+0.80+1.2%66.9067.3066.30456
66.20-0.80-1.2%67.0067.9066.1014,676
67.000.000.0%67.1068.8065.606,499
67.00-1.00-1.5%67.0068.0063.201,547
68.00-1.60-2.3%69.4069.4065.506,436
69.60-0.40-0.6%70.8071.0069.404,875
70.00-0.80-1.1%70.7070.7070.00101
70.80+0.70+1.0%70.5070.8070.00626
70.10+0.30+0.4%69.8070.9069.802,252
69.80-0.50-0.7%70.3070.3069.201,127
70.30-0.80-1.1%71.0071.0069.003,148
71.10-0.40-0.6%70.2072.4070.20996
71.50+2.20+3.2%69.3071.5069.303,874
69.30-2.00-2.8%70.1071.3069.306,239
71.30-1.10-1.5%70.0071.5070.002,236
72.40-0.10-0.1%72.5072.5070.601,246
72.50+0.20+0.3%72.5073.9071.301,471
72.30-2.20-3.0%74.1074.1072.30912
74.500.000.0%73.3074.6072.905,073
74.50+2.90+4.1%71.3074.8071.302,146
71.60-1.10-1.5%72.7072.7071.002,182
72.70+2.20+3.1%70.3072.8069.6011,472
70.50-0.80-1.1%71.0071.2070.50413
71.30-0.20-0.3%71.1071.9070.601,337
71.50+0.50+0.7%69.5071.5069.501,176
71.000.000.0%69.6071.0069.002,450
71.00-0.90-1.3%69.7071.9069.401,910
71.90+0.90+1.3%70.0071.9068.302,014
71.00-0.10-0.1%71.0071.6070.001,890
71.10-1.90-2.6%71.3072.0071.10858
73.00-1.00-1.4%72.0073.9070.108,931
74.00+1.60+2.2%72.0074.0069.701,942
72.40-0.60-0.8%72.0072.4072.00488
73.00-0.20-0.3%73.7073.7071.20792
73.20+0.40+0.5%72.9073.8069.203,701
Ticker
Dusseldorf:60Q
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Dusseldorf
Currency
EUR

What changed lately

Latest news

All Captor Therapeutics SA news

Captor Therapeutics SA on 6ix

Sector
Health care
Industry
Biotechnology
News releases
6 in all · newest May 30, 2023 · oldest 2022
Decks
23 decks · latest Jun 2, 2026

Where Captor Therapeutics SA is listed

ListingExchangeCountryCurrency
GPW:CTX · Home listingGPWPolandPLN
gettex:60QgettexGermanyEUR
LS Exchange:A3CNAXLS ExchangeGermanyEUR
Munich:60QMunichGermanyEUR
Frankfurt:60QFrankfurtGermanyEUR
Stuttgart:60QStuttgartGermanyEUR
Dusseldorf:60Q · This pageDusseldorfGermanyEUR
Lang & Schwarz:A3CNAXLang & SchwarzGermanyEUR

Cash and shares

Oct 2, 2025 · Captor Therapeutics — Investor Presentation (October 2025)

Shares outstanding
5,528,709

The slide these figures come from

Valuation

EV/sales 130× against a median of 0.9×: the highest of 6 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026

Enterprise value
260.5M PLN
P/E
Loss
EV/sales
130×
EV/EBITDA
Negative EBITDA
Price/book
5.1×
Gross margin
106.8%
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
0.0×
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Captor Therapeutics SA · GPW:CTXUS$81.11MUS$64.15Mn/a130×n/a5.1×n/a0.0×n/a
Rallybio Corporation · NASDAQ:RLYBUS$83.29M−US$7.40M3.1×−17.1×n/a0.9×n/a0.0×0.58
TuHURA Biosciences, Inc. · NASDAQ:HURAUS$82.20MUS$89.50Mn/an/an/a4.3×n/a0.5×2.81
3D Medicines, Inc. · HKEX:1244US$81.88MUS$48.45Mn/a0.9×n/a1.0×−49.9%0.3×n/a
Kintor Pharmaceutical Ltd · HKEX:9939US$81.70MUS$96.94Mn/a19.8×n/a5.0×−612.3%1.2×n/a
Nkarta, Inc. · NASDAQ:NKTXUS$81.38M−US$75.22Mn/an/an/a0.4×n/a0.0×1.67
Vaxart, Inc. · OTC:VXRTUS$79.89MUS$14.34M2.8×0.1×0.4×1.2×16.0%0.0×1.21
Sensorion SAS · EURONEXT:ALSENUS$79.63M−US$13.98Mn/an/an/a0.9×n/a0.0×n/a
Adocia SA · EURONEXT:ADOCUS$79.30MUS$77.84Mn/a48.1×n/an/an/an/an/a
Tiziana Life Sciences Ltd · NASDAQ:TLSAUS$78.98MUS$76.73Mn/an/an/an/an/an/a1.23
Nyrada, Inc. · ASX:NYRUS$78.76MUS$73.21Mn/an/an/a12.5×n/a0.0×n/a
Median of the othersUS$80.64MUS$60.83M2.9×0.9×0.4×1.1×−49.9%0.0×1.23

Forecasts

Analysts' consensus from EODHD, read Nov 21, 2026. Not 6ix's view and not investment advice.

Price target
91.90 PLN · Analysts' mean
EPS, year to Dec 2026
-5.20 · 1 analyst
Revenue, year to Dec 2026
44.6M · 3 analysts

Team and board

Officers

OfficerRole
Michał WalczakChief Executive Officer, Chief Scientific Officer
Adam ŁukojćChief Financial Officer
Anna PawlukChief Operating Officer

Board

DirectorRole
Adam ŁukojćChief Financial Officer
Anna PawlukChief Operating Officer
Michał WalczakChief Executive Officer, Chief Scientific Officer

Events

QuarterResultsShare move
Q2 2026Sep 3, 2026+0.4%
Q1 2026Jun 2, 2026+0.7%
Q3 2025Nov 21, 2025+0.4%
Q2 2025Sep 11, 2025+2.2%
Q1 2025Apr 15, 2025 · After close+0.6%
Q3 2024Nov 8, 2024 · After close−4.8%
Q2 2024Sep 5, 2024+10.5%
Q1 2024May 29, 2024 · After close−3.7%
Q3 2023Nov 28, 2023 · After close+0.7%
Q2 2023Sep 7, 2023 · After close−0.8%
All 17 quarters
QuarterResultsShare move
Q1 2023May 30, 2023 · Before open0.0%
Q4 2022Mar 1, 20230.0%
Q3 2022Nov 24, 2022 · After close+1.9%
Q2 2022Sep 2, 2022 · After close0.0%
Q1 2022May 30, 2022 · After close+1.1%
Q3 2021Nov 29, 2021 · After close−0.4%
Quarter to Jun 30, 2021Sep 30, 2021 · After close−1.1%

Open Events

Decks

DeckKindSlidesDate
Q1 2026 Earnings PresentationEarnings11 slidesJun 2, 2026
Investor Presentation (May 2026)Investor deck72 slidesMay 5, 2026
Investor Presentation (October 2025)Investor deck58 slidesOct 6, 2025
Investor Presentation (September 2025)Investor deck58 slidesSeptember 2025
Investor Presentation (July 2025)Investor deck69 slidesJul 30, 2025
Investor Presentation (October 2024)Investor deck58 slidesOctober 2024
Investor Presentation (October 2024)Investor deck58 slidesOctober 2024
H1 2024 Earnings PresentationEarnings24 slidesSep 10, 2024
Investor Presentation (March 2024)Investor deck20 slidesMar 11, 2024
Q3 2023 Earnings PresentationEarnings27 slidesDec 12, 2023
All 23 decks
DeckKindSlidesDate
Q3 2023 Earnings PresentationEarnings26 slidesDecember 2023
Investor Day (December 2023)Investor day21 slidesDec 1, 2023
Investor Presentation (October 2023)Investor deck55 slidesOctober 2023
H1 2023 Earnings PresentationEarnings26 slidesSep 7, 2023
Investor Presentation (September 2023)Investor deck56 slidesSep 1, 2023
Q1 2023 Earnings PresentationEarnings30 slidesMay 30, 2023
Investor Presentation (September 2022)Investor deck31 slidesSep 1, 2022
Investor Day (May 2022)Investor day27 slidesMay 18, 2022
Investor Day (May 2022)Investor day28 slidesMay 18, 2022
Investor Day (May 2022)Investor day37 slidesMay 18, 2022
Q3 2021 Earnings PresentationEarnings24 slidesNov 29, 2021
H1 2021 Earnings PresentationEarnings22 slidesOct 6, 2021
H1 2021 Earnings PresentationEarnings23 slidesOct 6, 2021

Open Decks

Financials

Annual, in PLN

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue4.66M15.8M13.2M9.16M3.99M1.45M016.0K474.0K
Cost of revenue5.31M9.40M6.30M2.09M741.0K6.60M4.46M2.59M95.0K
Gross profit-652.0K6.42M6.90M7.07M3.25M-6.60M-4.46M-2.57M379.0K
Research and development42.9M34.7M64.8M44.2M23.1M23.6M19.2M10.7M2.50M
Selling, general and administrative3.92M4.13M16.1M19.6M19.5M4.20M2.44M1.10M279.0K
Operating income-43.6M-39.0M-73.0M-38.4M-31.7M-12.2M-7.86M-4.13M-133.0K
Depreciation and amortization4.37M5.06M5.44M7.09M7.36M6.60M4.46M2.59M600.0K
EBITDA-39.2M-33.9M-67.6M-31.3M-24.4M-5.61M-3.40M-1.54M467.0K
Interest expense283.0K437.0K323.0K657.0K863.0K393.0K430.0K266.0K46.0K
Income before tax-42.0M-38.4M-70.5M-35.9M-32.6M-12.7M-8.31M-4.42M-180.0K
Income tax57.0K-26.0K-1.00K
Net income-42.0M-38.4M-70.6M-35.9M-32.6M-13.1M-8.74M-4.42M-180.0K
Earnings per share, basic-7.61-8.25-15.19-8,610.00-7,890.00-4.02-2.68-1.36-0.06
Earnings per share, diluted-8,240.00-7,480.00

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents10.7M39.3M75.7M71.0M117.9M10.7M12.3M2.45M1.59M
Short-term investments21.4M19.9M
Receivables1.22M38.3M12.6M9.68M11.7M2.59M1.88M4.02M515.0K
Inventory471.0K319.0K-515.0K
Current assets33.8M78.1M88.6M101.3M130.6M13.2M14.7M6.79M2.11M
Property, plant and equipment10.7M12.6M12.2M
Total assets40.0M87.5M97.3M113.0M143.5M25.8M25.3M18.1M5.12M
Accounts payable2.54M2.65M6.50M7.82M4.74M2.36M1.97M1.68M363.0K
Current liabilities14.9M20.0M26.7M13.4M16.4M20.0M15.2M7.23M3.54M
Long-term debt00000214.0K214.0K211.0K
Total debt3.58M5.64M3.78M6.95M8.18M12.4M10.3M10.9M2.83M
Total liabilities16.5M23.0M28.1M16.7M19.3M26.8M21.0M14.6M4.98M
Shareholders' equity23.5M64.5M69.2M96.3M124.2M-1.00M4.28M3.43M144.0K
Shares outstanding5.52M4.66M4.65M4.17M4.13M3.26M3.26M3.26M3.26M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-36.3M-31.9M-52.2M-22.9M-28.5M-595.0K4.39M-2.13M2.10M
Capital spending-210.0K-424.0K-3.00M-892.0K-5.11M-212.0K-229.0K-100.0K0
Free cash flow-36.5M-32.1M-55.2M-23.8M-33.6M-807.0K4.17M-2.23M2.10M
Cash from investing-21.1M273.0K19.9M-17.6M-5.11M-212.0K-229.0K-100.0K
Cash from financing28.9M-4.84M36.9M-6.33M140.9M-881.0K5.73M3.09M-513.0K
Change in cash-28.5M-36.4M4.67M-46.9M107.3M-1.69M9.89M861.0K1.58M

Open Financials

Cap table

Built by 6ix from Captor Therapeutics SA’s releases

Common shares
6,333,397
Fully diluted
6,333,397

Fully diluted

LineShares
Common shares6,333,397

Share count over time

CountShares
Nov 22, 20266,333,397

Open Cap table

Shareholders

HolderSharesValueAs of
State Street(R) SPDR(R) Portfolio Europe ETF104US$2,119Jun 30, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Adam ŁukojćChief Financial Officer · Since at least Nov 5, 2026
Anna PawlukChief Operating Officer · Since at least Nov 5, 2026
Michał WalczakChief Executive Officer, Chief Scientific Officer · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Captor Therapeutics SA.